Health care reform study: Massachusetts health insurance exchange fails to cut costs
March 10, 2011 by MassDevice staff
The conservative Pioneer Institute releases a report stating that the Massachusetts health insurance exchange has failed to attract small businesses, isn't controlling rising health insurance costs and faces imminent budgetary threats from national health care reform.
The Massachusetts health care reform law has been successful in reducing the ranks of the uninsured, but the benefit exchange set up by the landmark 2006 legislation has failed in its mission to reduce costs and faces serious hurdles from federal health care reform changes, according to a Boston, Mass.-based think tank.
The Pioneer Institute for Public Policy Research relayed those findings in a report, "Fixing the Massachusetts Health Exchange," released last night at an event at Harvard Medical School.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
- How to simplify consents
Navigation
NEWS
J&J's Synthes unit wins $16M ruling in patent fight with Globus Medical
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
ForSight Vision5 gets new CEO, closes $9.3M funding round
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Real-world results cast doubt on renal denervation for high blood pressure
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...
